Asthma Therapeutics in Major Developed Markets Growth & Trend to 2020 Radiant Insights, Inc
Summary Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Summary
Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
1.2 List of Figures 8<br />
2 Introduction 10<br />
2.1 Disease Introduction 10<br />
2.2 Epidemiology 10<br />
2.3 Etiology 11<br />
2.4 Pathophysiology 12<br />
2.5 Symp<strong>to</strong>ms 12<br />
2.6 Diagnosis 12<br />
2.7 Assessment of Disease Severity 13<br />
Access This Full Report @ http://www.radiant<strong>in</strong>sights.com/research/asthma-therapeutics-<strong>in</strong>major-developed-markets-<strong>to</strong>-<strong>2020</strong>-personalized-treatment-for-severe-asthma-<strong>to</strong>-drive-marketgrowth-despite-patent-expirations<br />
2.8 Treatment 15<br />
2.9 Treatment Algorithm 16<br />
2.10 Treatment Segments 18<br />
2.10.1 ICS Monotherapy for the Ma<strong>in</strong>tenance Treatment of <strong>Asthma</strong> 19<br />
2.10.2 S<strong>in</strong>gulair (montelukast sodium) as First-L<strong>in</strong>e Ma<strong>in</strong>tenance Therapy 21<br />
2.10.3 ICS/LABA Comb<strong>in</strong>ation Therapy 22<br />
2.10.4 Add-on Therapies 27<br />
3 Marketed Products 33<br />
3.1 Overview 33<br />
3.2 ICS for the Ma<strong>in</strong>tenance Treatment of <strong>Asthma</strong> 33<br />
3.2.1 Arnuity (fluticasone furoate) - GSK 33<br />
3.3 ICS/LABA Comb<strong>in</strong>ation Therapy for the Ma<strong>in</strong>tenance Treatment of <strong>Asthma</strong> 34<br />
3.3.1 Advair (fluticasone propionate and salmeterol x<strong>in</strong>afoate) - GSK 34
Change language